Prostaglandin G/H synthase 2
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Prostaglandin G/H synthase 2 as ChEMBL target CHEMBL4321, mapped to UniProt Q05769. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Prostaglandin G/H synthase 2 matters
Prostaglandin G/H synthase 2 is reviewed as Prostaglandin G/H synthase 2 (UniProt Q05769); the current evidence base includes 10 approved drugs, 1209 compounds, and 193 assays, with lead potency reaching pChEMBL 10.7.
Prostaglandin G/H synthase 2 Sequence length is 604 aa.
Review this target as Prostaglandin G/H synthase 2, mapped to UniProt Q05769. Sequence length is 604 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 10 approved drugs, 1209 compounds, and 193 assays for this target. The dominant activity type is IC50. CHEMBL499069 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL499069 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Prostaglandin G/H synthase 2 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q05769, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL499069
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL525247
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL501208
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL502555
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL500936
|
10.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LUMIRACOXIB
CHEMBL404108
|
2005 |
|
|
MELOXICAM
CHEMBL599
|
2000 |
|
|
ROFECOXIB
CHEMBL122
|
1999 |
|
|
CELECOXIB
CHEMBL118
|
1998 |
|
|
DICLOFENAC
CHEMBL139
|
1988 |
|
|
FLURBIPROFEN
CHEMBL563
|
1986 |
|
|
MECLOFENAMIC ACID
CHEMBL509
|
1980 |
|
|
IBUPROFEN
CHEMBL521
|
1974 |
|
|
INDOMETHACIN
CHEMBL6
|
1965 |